Early-stage BAP1-associated Malignancies trials recruiting in Maryland

Fewer than 3 recruiting trials found.

All Early-stage BAP1-associated Malignancies trials nationally

Cities in Maryland

Recruiting trials in Maryland

• Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
  NCT05960773 · Phase: Phase 2 · Ages: 18 Years to 120 Years · Sex: All (male and female) · Maryland: Bethesda